@article {DOLDO3303, author = {ELENA DOLDO and GAETANA COSTANZA and AMEDEO FERLOSIO and DANIELA PASSERI and SERGIO BERNARDINI and MARIA GIOVANNA SCIOLI and DONATELLA MAZZAGLIA and SARA AGOSTINELLI and DONATELLA DEL BUFALO and BERNARD CZERNOBILSKY and AUGUSTO ORLANDI}, title = {CRBP-1 Expression in Ovarian Cancer: A Potential Therapeutic Target}, volume = {34}, number = {7}, pages = {3303--3312}, year = {2014}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Cellular retinol binding protein-1 regulates retinol bioavailability and contributes to cell differentiation maintenance, but its role in ovarian carcinogenesis remains uncertain. We investigated CRBP-1 expression in ovarian tumors and CRBP-1 signaling-regulated pathways. Materials and Methods: We performed immunohistochemistry, methylation-specific PCR, gene copy number analysis in ovarian tumors and proliferation/apoptosis evaluation, gene array, blot and real-time PCR in CRBP-1-transfected A2780 ovarian cancer cells. Results: CRBP-1 expression was reduced or absent in G2 and G3 ovarian carcinomas. CRBP-1 silencing in 60\% of G2 and 66.7\% of G3 carcinomas was due to CRBP-1 promoter methylation. A2780 CRBP-1-transfected cells showed increased retinol-induced apoptosis, retinoid-induced reduced clonogenicity and down-regulation of proliferation and transcription genes, including AKT1, AKT3, EGFR, FOS, JUN, STAT1 and STAT5A. Conclusion: CRBP-1 loss in G2/G3 ovarian carcinomas and increased apoptotic susceptibility to retinoids in CRBP-1-transfected-A2780 cells suggest CRBP-1 screening as a target to ensure efficacy of an adjuvant retinoid therapy.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/34/7/3303}, eprint = {https://ar.iiarjournals.org/content/34/7/3303.full.pdf}, journal = {Anticancer Research} }